Company: ABBV
Filing Date: 2025-05-09
Form Type: 10-Q
Source: 0001551152-25-000029
Chunk: 48

Company: AbbVie Inc.
Filing Date: 2025-05-09
Form: 10-Q
Item: Part I, Item 1
Chunk 48
---
ATIONS

Net Revenues

The comparisons presented at constant currency rates reflect comparative local currency net revenues at the prior year’s foreign exchange rates. This measure provides information on the change in net revenues assuming that foreign currency exchange rates had not changed between the prior and current periods. AbbVie believes that the non-GAAP measure of change in net revenues at constant currency rates, when used in conjunction with the GAAP measure of change in net revenues at actual currency rates, may provide a more complete understanding of the company’s operations and can facilitate analysis of the company’s results of operations, particularly in evaluating performance from one period to another.

Three months endedMarch 31,Percent changeAt actual currency ratesAt constant currency rates(dollars in millions)20252024United States$9,979 $9,041 10.4 %10.4 %International3,364 3,269 2.9 %8.3 %Net revenues$13,343 $12,310 8.4 %9.8 %

2025 Form 10-Q | 27

The following table details AbbVie’s worldwide net revenues: Three months endedMarch 31,Percent changeAt actual currency ratesAt constant currency rates(dollars in millions)20252024ImmunologySkyriziUnited States$2,919 $1,656 76.2 %76.2 %International506 352 43.9 %52.3 %Total$3,425 $2,008 70.5 %72.0 %RinvoqUnited States$1,220 $725 68.3 %68.3 %International498 368 35.3 %42.8 %Total$1,718 $1,093 57.2 %59.7 %HumiraUnited States$744 $1,771 (58.0)%(58.0)%International377 499 (24.4)%(19.5)%Total$1,121 $2,270 (50.6)%(49.5)%NeuroscienceVraylarUnited States$763 $692 10.3 %10.3 %International2 2 13.1 %20.2 %Total$765 $694 10.3 %10.3 %B